Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2043538 | 0.88 | KDM4E (0.42) | MAPTPOLBKDM4EL3MBTL1HSD17B10 | |
| SCHEMBL11931239 | 0.87 | L3MBTL1 (0.52) | MAPTPOLBKDM4EL3MBTL1HSD17B10 | |
| SCHEMBL11931247 | 0.86 | MAPT (0.48) | MAPTPOLBKDM4EL3MBTL1HSD17B10 | |
| SCHEMBL2041483 | 0.86 | KDM4E (0.49) | MAPTPOLBKDM4EL3MBTL1HSD17B10 | |
| SCHEMBL14013824 | 0.80 | PRKAB2 (0.39) | MAPTKDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL902441 | 0.77 | MAPT (0.42) | MAPTPOLBKDM4EL3MBTL1HSD17B10 | |
| SCHEMBL11931243 | 0.76 | L3MBTL1 (0.51) | MAPTPOLBKDM4EL3MBTL1HSD17B10 | |
| SCHEMBL14698589 | 0.76 | MAPT (0.49) | MAPTPOLBKDM4EL3MBTL1HSD17B10 | |
| SCHEMBL8570609 | 0.76 | MAPT (0.62) | MAPTPOLBKDM4EL3MBTL1HSD17B10 | |
| SCHEMBL2044748 | 0.74 | KDM4E (0.42) | MAPTPOLBKDM4EL3MBTL1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1942900-B1 | USE OF PYRAZOLO [1,5-A] PYRIMIDINE DERIVATIVES FOR INHIBITING KINASES METHODS FOR INHIBITING PROTEIN KINASES | MERCK SHARP & DOHME (US) | 2015-06-03 | — | — | EP | disclosed |
| EP-2516008-B1 | NOVEL ANTIVIRAL COMPOUNDS | UNIV LEUVEN KATH (BE) | 2014-04-16 | — | — | EP | disclosed |
| US-20120316161-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-12-13 | — | — | US | disclosed |
| EP-2516008-A1 | NOVEL ANTIVIRAL COMPOUNDS | Katholieke Universiteit Leuven (BE) | 2012-10-31 | — | — | EP | disclosed |
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| EP-1931676-B1 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORP (US) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011076765-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-06-30 | — | — | WO | disclosed |
| US-7776865-B2 | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776865-B2 | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| US-7449488-B2 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449488-B2 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| WO-2007044410-A1 | PYRAZOLO [1,5-A] PYRIMIDINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007044441-A2 | USE OF PYRAZOLO [1 , 5 -A] PYRIMIDINE DERIVATIVES FOR INHIBITING PROTEIN KINASES METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070083044-A1 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070083044-A1 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| WO-2007041712-A1 | PYRAZOLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316161-A1 | NOVEL ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | MAPT 3089/4885POLB 134/4885KDM4E 2080/4885 |
| US-20070082900-A1 | Methods for inhibiting protein kinases | PIM1, AURKC, PIM3 | MAPT 2170/4885POLB 1685/4885KDM4E 1092/4885 |
| US-20070083044-A1 | Pyrazolopyrimidines as protein kinase inhibitors | CHEK1, CHEK2, BUB1 | MAPT 1518/4885POLB 1399/4885KDM4E 926/4885 |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | PIM1, AURKC, PIM3 | MAPT 2170/4885POLB 1685/4885KDM4E 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.